This randomized, controlled clinical trial investigates the potential cardioprotective effects of melatonin in women diagnosed with peripartum cardiomyopathy (PPCM). The study aims to determine whether melatonin supplementation improves left ventricular (LV) function, promotes reverse remodeling, and reduces systemic inflammation. Participants receive standardized heart failure therapy with or without adjunctive melatonin, and outcomes are assessed using echocardiographic parameters (including LVEF, LV dimensions, and global longitudinal strain) and inflammatory biomarkers (e.g., CRP, IL-6, TNF-α). The study hypothesizes that melatonin's antioxidant and anti-inflammatory properties will enhance cardiac recovery, improve functional capacity, and potentially reduce morbidity in PPCM patients.

Start Date20 Dec 2026

Sponsor / Collaborator

Tanta University

[+1]

IRCT20251109067930N1

/ SuspendedPhase 2/3IIT

Studying the effect of oral selenium on the size of non-malignant thyroid nodules

Start Date21 Dec 2025

Sponsor / Collaborator-

CTRI/2025/12/098593

/ Not yet recruitingPhase 2IIT

Selenium as an adjunctive therapy in patients with Schizophrenia : An MRS-Based open Label Study - NIL

Start Date19 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Selenium

100 Translational Medicine associated with Selenium

100 Patents (Medical) associated with Selenium

13,017

Literatures (Medical) associated with Selenium

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Selenium alleviates Staphylococcus aureus-induced mastitis by modulating mitochondrial dynamics and inhibiting the ROS/NLRP3/Pyroptosis pathway

Article

Author: Zhang, Junhao ; Hu, Changmin ; Yang, Jinghan ; Du, Yanting ; Hu, Yanjun ; Qi, Xue ; Jiang, Mingxuan

BACKGROUND:

The pathogenesis of bovine mastitis involves inflammation and cell death, with pyroptosis being a key factor in its development. Currently, antibiotics remain the primary therapeutic option for bovine mastitis, however, the increasing prevalence of antibiotic resistance constitutes a major public health threat. Selenium (Se) has been reported to alleviate inflammation primarily through its antioxidant properties, but the mechanism by which Se regulates pyroptosis in bovine mastitis remains unclear.

METHODS AND RESULTS:

In this study, an in vitro mastitis model was established by infecting MAC-T cells with inactivated Staphylococcus aureus (S. aureus) (MOI = 10, 12 h). The results revealed that the mitochondrial membrane potential of the MAC-T cells in the infection group decreased significantly. Moreover, the accumulation of Reactive oxygen species (ROS) was accompanied by the activation of NOD-like receptor family containing pyrin domain 3 (NLRP3), the expression of the pyroptosis-related genes gasdermin D amino terminal fragment (GSDMD-N), and cysteine aspartate specific protease 1 (cleaved-caspase 1). Pretreatment with Se, the NLRP3 inhibitor MCC950 and the antioxidant N-acetylcysteine (NAC) attenuated mitochondrial damage, ROS accumulation, and the inhibition of pyroptosis. An in vivo mastitis model was established in mice fed a high-selenium diet (containing 1.5 mg/kg Se) and intramammarily injected with inactivated S. aureus (1 × 10⁸ CFU/mL). Histological analysis revealed intact alveolar structure and reduced inflammatory cell infiltration in mice fed the high-selenium diet. The expression of the inflammasome NLRP3 downregulated, and the expression of GSDMD-N, a direct executor of pyroptosis, upregulated.

CONCLUSION:

Our in vitro and in vivo results confirmed that Se alleviate mitochondrial damage and pyroptosis by inhibiting the NLRP3 pathway, ultimately alleviating mastitis.

01 Apr 2026·Clinical Nutrition ESPEN

The role of nutrition in prostate cancer risk, progression, and mortality: A comprehensive review

Review

Author: Sundaresan, Vinaik ; Souroujon Torun, Ariela A ; Golos, Aleksandra ; Leapman, Michael S ; Gomez-Santamaría, Olga A ; Casilla-Lennon, Marianne

BACKGROUND:

Prostate cancer (PCa) is one of the most prevalent malignancies among men worldwide, yet evidence-based nutritional recommendations for its prevention and progression remain limited. Growing research indicates that diet may play a significant role in modulating PCa risk, tumor behavior, and mortality.

OBJECTIVE:

This narrative review synthesizes current evidence on major dietary components, including carbohydrates, protein sources, fats, vegetables, vitamins, and minerals. It evaluates their associations with PCa incidence, progression, and disease-specific mortality.

METHODS:

This narrative review synthesized evidence from PubMed/MEDLINE, Embase, and Web of Science (up to 2025), including randomized trials, observational studies, and meta-analyses, to evaluate associations between dietary factors and prostate cancer incidence, progression, and mortality.

FINDINGS:

High intake of simple sugars and refined carbohydrates is associated with elevated PCa risk, whereas complex carbohydrates are associated with a more favorable metabolic profile. Evidence consistently supports increased fish consumption and suggests potential benefit from soy products. In contrast, high intake of red/processed meats and full-fat dairy may increase the risk of aggressive disease. Total and saturated fat intake is associated with poorer outcomes, although evidence on omega-3 fatty acids is mixed. Cruciferous vegetables show a strong protective factor, supported by epidemiologic data, whereas evidence for allium vegetables is emerging. Findings for micronutrients were highly heterogeneous: lycopene and physiologic vitamin E levels may confer benefit, whereas high-dose vitamin A derivatives, supplemental folic acid, selenium, and excessive dairy-derived calcium may increase PCa risk.

CONCLUSION:

Although evidence is often inconsistent, several dietary patterns appear promising for PCa prevention and decreasing mortality. Emphasizing complex carbohydrates, fish, soy, plant-based fats, and cruciferous vegetables-while limiting simple sugars, red/processed meats, whole milk, saturated fats, and unnecessary supplementation-may support improved outcomes. High-quality randomized trials remain urgently needed to clarify causality and refine clinical nutrition guidance for PCa.

01 Apr 2026·ANIMAL REPRODUCTION SCIENCE

Ferroptosis-driven cryoinjury in porcine testicular tissue: Mechanisms, antioxidant-based cryoprotection, and translational strategies for fertility preservation

Review

Author: Wan, Pengcheng ; Yang, Baigao ; Zhang, Hang ; Aderibigbe, David Olusola ; Zhao, Xueming ; Pan, Hongmei ; Zhang, Xiaomeng ; Osaiyuwu, Osamede Henry ; Dong, Jianhua ; Song, Haoran ; Shahzad, Muhammad ; Kolachi, Hubdar Ali ; Ayantoye, Jesse Oluwaseun

Porcine testicular tissue cryopreservation underpins genetic resource banking and fertility preservation. However, conventional dimethyl-sulfoxide (DMSO) protocols recover only a fraction of viable spermatogonial stem cells (SSCs) and often compromise downstream function. This review synthesizes mechanistic evidence showing that cryoinjury is not solely a problem of ice formation and osmotic stress; it is amplified by a surge of reactive oxygen species that peroxidize the exceptionally polyunsaturated, low-cholesterol membranes of porcine germ cells. Together with high testicular iron flux, these features create conditions in which ferroptosis dominates freeze-thaw lethality. In contrast to previous reviews that chiefly attribute cryodamage to generic oxidative stress and advocate broad antioxidant supplementation, this review defines ferroptosis as the dominant mechanism of regulated cell death and proposes targeted antioxidant strategies accordingly. We summarize how glutathione peroxidase-4 (GPX4) insufficiency, labile Fe²⁺, and lipid radical propagation converge during cryostress, and we compile emerging evidence from large animals that targeting this pathway improves outcomes. Lipid-directed radical-trapping agents (ferrostatin-1, liproxstatin-1), vitamin-E analogs, selenium (to support GPX4 activity), and iron chelators each reduce post-thaw lipid peroxidation, preserve membrane and mitochondrial integrity, and enhance sperm/SSC performance. We discuss synergistic combinations and practical delivery considerations, including nano- and liposomal carriers for poorly soluble antioxidants. Translational sections integrate data from xenografting/autografting models showing that cryopreserved testicular tissue can reinitiate spermatogenesis and yield fertile gametes, underscoring the value of mechanism-informed media for both livestock and human fertility biobanking. Finally, we outline priorities for porcine-specific ferroptosis assays, standardized antioxidant-enriched freezing protocols, dose optimization, and long-term reproductive endpoints. Collectively, the evidence supports a paradigm shift: ferroptosis is a central driver of cryodamage in porcine testicular tissue, and ferroptosis-targeted, antioxidant-based cryoprotection offers a rational path to higher SSC survival, improved graft architecture, and better translational fertility outcomes.

News (Medical) associated with Selenium

27 Oct 2025

·www.einpresswire.com

64K Cellssense Featured in Frontiers in Aging for Pioneering Review on Nanoengineered Mitochondria

Company outlines how nanoengineering approaches may advance studies of mitochondrial function and cellular health. This publication in Frontiers in Aging represents a synthesis of emerging data on mitochondrial nanoengineering, reflecting our commitment to peer-reviewed science and measurable longevity research.” — Thomas Miller, Head of the 64K Cellssense International Research Center LAUSANNE, SWITZERLAND, October 27, 2025 / EINPresswire.com / -- 64K Cellssense announced its Research and Innovation Center published a review article in Frontiers in Aging , a leading Swiss academic journal. The article, titled “Nanoengineered Mitochondria for Mitochondrial Dysfunction and Anti-Aging Interventions,” explores the emerging field of mitochondrial nanoengineering and its implications for maintaining cellular function and energy balance. The review provides a comprehensive overview of recent advances in nanoengineered mitochondria — a rapidly growing focus in life sciences. It details how nanoscale design can support mitochondrial integrity, optimize metabolic efficiency, and enhance resilience under cellular stress. The review offers an international perspective on how nanotechnology is shaping next-generation mitochondrial research, reflecting 64K Cellssense’s contribution to the global dialogue on healthy cellular aging. Within 64K Cellssense’s 12-Dimensional Longevity Framework, mitochondrial performance is studied as a core determinant of cellular function. The review proposes a research framework that integrates nanoengineering strategies to optimize mitochondrial energy systems and mitigate oxidative imbalance at the cellular level. The article also summarizes key natural mitochondrial regulators — including α-ketoglutarate (AKG), ergothioneine (EGT), resveratrol, CoQ10, and selenium — and highlights how nano-delivery approaches may improve their stability and targeted bioavailability in experimental models. Building on these foundational insights, 64K Cellssense continues to develop its proprietary MPNutria ® Nano-Nutrition Delivery Technology, based on metal–phenolic network (MPN) nanostructures — a technology lineage related to the 2025 Nobel Prize -winning research on metal-organic frameworks (MOFs). This technology exemplifies how the brand translates cutting-edge scientific concepts into scalable, experimentally validated applications. While mitochondrial nanoengineering shows considerable potential, the review notes that further research is required to address challenges related to delivery consistency, biological compatibility, and scalable production. The Research and Innovation Center of 64K Cellssense has collaborated on projects with academic and clinical partners in Switzerland, the United States, Australia and China, including, among others, ETH Zurich, Harvard University and Clinique Eden Suisse. Collectively, these efforts reinforce 64K Cellssense’s long-term mission to drive data-driven innovation in cellular health, bridging academic research and practical, scalable applications in life sciences. Anastasia Y. Vitagenix Technology Limited email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

14 Mar 2025

·www.drugs.com

Metal Mixtures During Pregnancy May Lower Midlife Hypertension Risk

FRIDAY, March 14, 2025 -- Optimizing copper, manganese, and vitamin B12 during pregnancy can help lower the risk for high blood pressure and hypertension in midlife, according to a study published online March 6 in Hypertension to coincide with the American Heart Association Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2025 Scientific Sessions, held from March 6 to 9 in New Orleans. Mingyu Zhang, Ph.D., from Harvard Medical School in Boston, and colleagues measured nonessential and essential metals in red blood cells along with folate and vitamin B12 in plasma during pregnancy (participants enrolled 1999 to 2002) to examine long-term associations with midlife blood pressure and hypertension. Midlife blood pressure was measured from 2017 to 2021. A total of 493 women were followed for a median of 18.1 years. The researchers found that a doubling of copper and manganese was associated with 0.75 and 0.80 times the risk for hypertension, respectively, after adjustment. A slightly increased risk for hypertension was seen in association with higher cesium and selenium, but the 95 percent confidence intervals were wide and crossed the null. A doubling of vitamin B12 was associated with 3.64- and 2.52-mm Hg lower systolic and diastolic blood pressure, respectively. There was a monotonic association for the essential metal mixture with lower blood pressure, while threshold effects were seen for its association with hypertension. "These findings suggest that optimizing essential metal levels during pregnancy, particularly, copper and manganese, along with vitamin B12, may offer protective benefits against high blood pressure and hypertension in midlife," the authors write.

AHAClinical Study

07 Mar 2025

·www.drugs.com

Select Vitamins, Minerals During Pregnancy Protect Heart Health Later

FRIDAY, March 7, 2025 -- Getting essential vitamins and minerals during pregnancy can help a woman maintain healthy blood pressure into middle age, new research suggests. High levels of the minerals copper and manganese in pregnant women were associated with lower blood pressure decades later, as well as a reduced risk of high blood pressure , researchers reported. Higher levels of vitamin B12 also were associated with lower blood pressure in later life, according to findings published March 6 in the journal Hypertension . “Optimizing these essential metals, minerals and vitamins -- particularly copper, manganese and vitamin B12 -- during pregnancy may offer protective benefits against hypertension in midlife, an especially critical time period for women’s future cardiovascular risk in later life,” lead researcher Mingyu Zhang , an epidemiologist at Beth Israel Deaconess Medical Center in Boston, said in a news release. For the study, his team analyzed data from an ongoing long-term study of nearly 500 pregnant women recruited between 1999 and 2002. The women underwent blood testing during their pregnancy for their levels of healthy essential minerals, such as copper, magnesium, manganese, selenium and zinc, researchers said. They also were tested for levels of folate and vitamin B12. After nearly 20 years of follow up, researchers checked in again with the women, who’d now reached an average age of 51. The women’s blood pressure was tested during this check in, and was considered high if greater than 130/80 or if they’d been prescribed high blood pressure meds. Results showed that if women had doubled levels of copper and manganese in their blood during pregnancy, their risk of midlife high blood pressure was 25% and 20% lower, respectively. Doubled levels of vitamin B12 also contributed to lower blood pressure, but researchers noted that about 95% of participants had B12 levels within the normal range. Copper, manganese, selenium and zinc all lowered blood pressure, and the higher the levels, the more blood pressure benefitted later in life, researchers found. However, the findings should not be interpreted as recommendations, since researchers were unable to tell whether women got these vitamins and minerals from food, dietary supplements or other sources, Zhang said. “More research including clinical trials is needed to determine the optimal dietary intake of these minerals and micronutrients,” Zhang said. Researchers hope to ultimately identify women at high risk for developing high blood pressure later in life and intervene during pregnancy, either with enhanced nutrition or supplements. These results were scheduled for presentation Saturday at an American Heart Association meeting in New Orleans. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical Study

100 Deals associated with Selenium

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Cardiotoxicity	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Chagas Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Chronic Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
end organ damage	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Functional disorder	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Huntington Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Infarction	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Keshan Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Myocardial Infarction	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01611896 (GRASS, Pubmed \| Eur Thyroid J)	Not Applicable	Graves Disease	430	Selenium supplementation	ihsnvftsut(rfdqqzlmqi) = dkudopbwol mplsisfvyp (tkhwacgmbg )	Negative	12 Dec 2025
				Placebo	ihsnvftsut(rfdqqzlmqi) = enabspiohy mplsisfvyp (tkhwacgmbg )
AACR2018	Phase 1	Female Genital Neoplasms	-	Selenious acid/carboplatin/paclitaxel	lwynpisgfk(datorcoata) = bzmirhbefk skhuinmgll (pksvviymsg ) View more	-	01 Jul 2018
ASCO2014	Not Applicable	Second Primary Neoplasms	-	Selenium	hdhkftklxo(wxppdiytmv) = hmpnmfdqzi swuivnxdpe (pqbzuxqvyh, 0.77 - 2.38)	-	20 May 2014
				Placebo	hdhkftklxo(wxppdiytmv) = lmlevziiut swuivnxdpe (pqbzuxqvyh )
Pubmed \| Cochrane Database Syst Rev	Not Applicable	Hashimoto Disease	463	Selenium supplementation	mhbenkbrin(rfocelkhkw): RR = 4.67 (95% CI, 1.61 - 13.5), P-Value = 0.004	-	06 Jun 2013
				Selenium
ASCO 12010 \| ASCO 22010	Phase 3	Non-small cell lung cancer stage I	-	selenium (Se) supplementation (Selenized yeast 200 micrograms)	ijulboktda(pvngfcoxdk) = exbzmhklqz yxwxsibmdk (ukrkdoljua ) View more	Negative	20 Jun 2010
				Placebo	ijulboktda(pvngfcoxdk) = ngyootdvxn yxwxsibmdk (ukrkdoljua ) View more
German Working Group on Trace Elements and Electrolytes (ASTRO2009)	Phase 2	Head and Neck Neoplasms selenium deficiency	40	Selenium supplementation	sepxxutwek(txptocxmkq) = qjrpwoxyun adnhsgvkyb (bhbimdqvtg ) View more	Negative	01 Nov 2009
				Control group (no selenium supplementation)	sepxxutwek(txptocxmkq) = bxgiegnsek adnhsgvkyb (bhbimdqvtg ) View more
ASCO2009	Phase 2	Head and Neck Neoplasms	39	selenium (Group A)	mdagwpjitz(dxycwcyqlj) = lxderjhved euvpzxfyuo (yrihgdxuke ) View more	Negative	20 May 2009
				selenium (Group B)	mdagwpjitz(dxycwcyqlj) = neexfsmlyc euvpzxfyuo (yrihgdxuke ) View more
ASCO2008	Phase 2	Prostatic Cancer	140	Placebo	umfmhcpkee(qnhinzbnlm) = htgxywcyoo myzefosjxe (tblyjawmrr )	Negative	20 May 2008
				200µg/day Selenium	umfmhcpkee(qnhinzbnlm) = uobkzuhwvl myzefosjxe (tblyjawmrr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Selenium

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation